Again, we tried to address this in the written answers to some of the questions we undertook to follow up on, on Monday. We certainly don't see that. Actual applications—what we call new drug submissions—to Health Canada for new active substances, in other words new innovative medicines, are actually up in the past fiscal year.
Since the regulations were finally adopted, and with these changes coming into force on the horizon, we're seeing an uptick in drugs coming to Canada, not a lowering. Then if you break it down quarterly, which we did in our answer, you see the same general trend. For the most recent quarter, it's actually above the average over the last three years. When you look at it quarterly, it's slightly above, 9.8 versus 9.